Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Light Horse Therapeutics has developed a proprietary function-first drug discovery platform that uses precision genome editing and high-throughput screening to identify cryptic, chemically accessible sites on challenging protein targets. The company’s initial pipeline includes several preclinical programs focused on oncology. In January 2025, it announced a $62 million Series A financing and a multi-target collaboration with Novartis worth up to $1 billion in milestones[2][6]. No clinical results have been disclosed as all programs are currently preclinical.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Light Horse Therapeutics.